BL-M02D1

Phase 2Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

BL-M02D1 is one of 84 small molecule programs targeting Gastrointestinal Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Gastrointestinal TumorsActive, not recruiting

Breast CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Gastrointestinal TumorsPhase 1

Active, not recruiting

Breast CancerPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Lexiscan

Astellas

Preclinical

1 2

Voltaren

Novartis

Preclinical

1 3

Zolymbus

AbbVie

Preclinical

1 4

Blenoxane

Bristol-Myers Squibb

Preclinical

1 5

BL-M02D1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 6

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 8

Duragesic-100

CCephalon

Preclinical

2 9

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 10

Spravato

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1/2·NCT05949619·14 enrolled

Breast Cancer1 trial

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer or Other Solid Tumors

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05339685·82 enrolled

Gastrointestinal Tumors1 trial

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05385692·22 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for BL-M02D1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BL-M02D1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BL-M02D1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

BL-M02D1

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Breast Cancer1 trial

Gastrointestinal Tumors1 trial

References

Drug Info

Quick Facts

Related News